<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04679324</url>
  </required_header>
  <id_info>
    <org_study_id>19-005222</org_study_id>
    <nct_id>NCT04679324</nct_id>
  </id_info>
  <brief_title>The Role of Mucosal Microbiome in the Development, Clearance and Recurrence of Clostridioides Difficile Infection</brief_title>
  <official_title>The Role of Mucosal Microbiome in the Development, Clearance and Recurrence of Clostridiodes Difficile Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is being done to identify types of bacteria associated with the lining of the large&#xD;
      intestine in people who have recently been diagnosed with C. difficile infection to determine&#xD;
      if there are features associated with development, clearance, and recurrence of disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients who were recently diagnosed with C. difficile infection will undergo assessment of&#xD;
      both before treatment and after completing treatment to study the presence of C. difficile in&#xD;
      the colonic mucosa pre as well as assessment for microbiome and patient/clinical factors that&#xD;
      may contribute to disease recurrence. Assessment will include sigmoid colon biopsies, blood&#xD;
      draw, stool samples and surveys.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 23, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Disease recurrence</measure>
    <time_frame>8 weeks post treatment of C.difficile infection</time_frame>
    <description>Based on clinical stool testing and symptoms</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in mucosal presence of C. difficile</measure>
    <time_frame>Baseline, approximately 1-14 days post treatment of C. difficile infection</time_frame>
    <description>Identification of C. difficile within the colonic mucosa on stained slides from sigmoid biopsy samples</description>
  </secondary_outcome>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Clostridioides Difficile Infection</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Sigmoid colon biopsies, stool samples, blood&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients recently diagnosed with C. difficile infection (not defined as recurrent) without&#xD;
        underlying inflammatory GI conditions&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults aged 18 and over&#xD;
&#xD;
          -  Confirmed C. difficile infection based on positive C. difficile toxin PCR testing and&#xD;
             clinical evidence of diarrhea&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known active pregnancy&#xD;
&#xD;
          -  Prior diagnosis of C. difficile infection within 2 months of this diagnosis&#xD;
&#xD;
          -  Other known active gastrointestinal infectious process&#xD;
&#xD;
          -  Vulnerable adults&#xD;
&#xD;
          -  Any other disease(s), condition(s) or habit(s) that would interfere with completion of&#xD;
             study, or in the judgment of the investigator would potentially interfere with&#xD;
             compliance to this study or would adversely affect study outcomes&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Purna Kashyap, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Heather Lekatz</last_name>
    <phone>507-538-1206</phone>
    <email>lekatz.heather@mayo.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dan Schupack, M.D.</last_name>
      <phone>507-284-4824</phone>
      <email>schupack.daniel@mayo.edu</email>
    </contact>
    <contact_backup>
      <last_name>Heather Lekatz</last_name>
      <phone>507-538-1206</phone>
      <email>lekatz.heather@mayo.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>December 9, 2020</study_first_submitted>
  <study_first_submitted_qc>December 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 22, 2020</study_first_posted>
  <last_update_submitted>October 5, 2021</last_update_submitted>
  <last_update_submitted_qc>October 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Purna C. Kashyap, MBBS</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Clostridium Infections</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

